A Multicenter, Open-Label Trial to Evaluate the Overall Performance of the Zalviso System (Sufentanil Sublingual Tablet System) 15 mcg
Latest Information Update: 05 Mar 2024
At a glance
- Drugs Sufentanil (Primary)
- Indications Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors AcelRx Pharmaceuticals
- 09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc.
- 08 Mar 2018 According to an AcelRx Pharmaceuticals media release, the company intends to submit results from this trial together with results of earlier phase 3 studies (IAP309, IAP310 and IAP311) as part of resubmission of a New Drug Application to the FDA in the second quarter of 2018.
- 01 Aug 2017 According to an AcelRx Pharmaceuticals media release, the company intends to submit results from this trial together with results of earlier phase 3 studies (IAP309, IAP310 and IAP311) as part of resubmission of a New Drug Application to the FDA by the end of 2017.